Scopolamine in Bipolar Depression

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a single-site, randomised, double-blind, placebo-controlled, parallel, phase IIb clinical trial. The primary objective of the SCOPE-BD study is to investigate the efficacy and safety of IV Scopolamine, compared to placebo, in reducing severity of depression in individuals with bipolar disorder who are experiencing a depressive episode of at least moderate severity
Epistemonikos ID: ad3ecfc4b6cccf2286bac555dbab7f8bc99f2129
First added on: May 06, 2024